scholarly journals Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma

2008 ◽  
Vol 82 (2) ◽  
pp. 194-199 ◽  
Author(s):  
F. FARACE ◽  
C. MATHIOT ◽  
M. BRANDELY ◽  
T. TURSZ ◽  
T. DORVAL ◽  
...  
Keyword(s):  
Phase I ◽  
Interferon Gamma ◽  
Immune Activation ◽  
Phase I Trial ◽  
Interleukin 2 ◽  
Recombinant Interferon ◽  
Recombinant Interleukin 2

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.

1990 ◽  
Vol 8 (7) ◽  
pp. 1269-1276 ◽  
Author(s):  
B G Redman ◽  
L Flaherty ◽  
T H Chou ◽  
A al-Katib ◽  
M Kraut ◽  
...  
Keyword(s):  
Phase I ◽  
Interferon Gamma ◽  
Phase I Trial ◽  
Interleukin 2 ◽  
Cell Activity ◽  
Ifn Gamma ◽  
Recombinant Interferon ◽  
Lak Cell ◽  
Recombinant Interleukin 2 ◽  
Lak Cell Activity

Twenty-six patients with metastatic cancer were entered into a phase I trial of concurrent recombinant interleukin-2 (IL-2) and recombinant interferon-gamma (IFN-gamma). IL-2 was administered as a continuous intravenous infusion for 5 days. IFN-gamma was administered by a daily intramuscular (IM) injection during the 5 days of IL-2 administration. Treatment was repeated twice after 9-day rest periods. After a 2-week rest, patients without evidence of tumor progression were retreated. Natural killer (NK)- and lymphokine-activated killer (LAK)-cell activity were assayed in each patient before treatment, on day 1, and on day 5 of each cycle. Constitutional symptoms occurred in most patients but were not dose-limiting. Other toxicities included hypotension responsive to fluids, transient elevations in liver function tests, erythema/pruritus, eosinophilia, and transient leukopenia/thrombocytopenia. The maximum-tolerated dose (MTD) of the combination was 1 x 10(6) U/m2/d of IL-2 combined with 0.50 mg/m2/d of IFN-gamma. The dose-limiting toxicity was pulmonary manifesting as rales and shortness of breath. The dose of the combination that resulted in the optimal generation of in vivo LAK-cell activity was a dose of at least 0.25 mg/m2/d of IFN-gamma combined with 1 x 10(6) U/m2/d of IL-2. Objective clinical responses were seen in five of 26 patients. These included a partial response of 2 months duration in a patient with non-Hodgkin's lymphoma (NHL), mixed responses in a patient with NHL and two patients with renal cell carcinoma (RCC), and an ongoing assessable response in a patient with bone metastases from RCC. The recommended dose for phase II trials of this combination is 0.50 mg/m2 of IFN-gamma and 1 x 10(6) U of IL-2.

Immunological Evaluation of Pediatric Cancer Patients Receiving Recombinant Interleukin-2 in a Phase I Trial

1992 ◽  
Vol 11 (4) ◽  
pp. 274-285 ◽  
Author(s):  
Robert L. Truitt ◽  
Victoria Piaskowski ◽  
Phyllis Kirchner ◽  
Laura McOlash ◽  
Bruce M. Camitta ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Pediatric Cancer ◽  
Phase I Trial ◽  
Interleukin 2 ◽  
Pediatric Cancer Patients ◽  
Recombinant Interleukin 2 ◽  
Immunological Evaluation

Phase I Trial of Combined Recombinant Interleukin-2 with Levamisole in Patients with Advanced Malignant Disease

1994 ◽  
Vol 17 (4) ◽  
pp. 344-347 ◽  
Author(s):  
Timothy G. Call ◽  
Edward T. Creagan ◽  
Stephen Frytak ◽  
Jan C. Buckner ◽  
Carol van Haelst-Pisani ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Malignant Disease ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma

1988 ◽  
Vol 6 (3) ◽  
Author(s):  
PaulB. Chapman ◽  
JonathanE. Kolitz ◽  
ThomasB. Hakes ◽  
JaniceL. Gabrilove ◽  
Karl Welte ◽  
...  
Keyword(s):  
Phase I ◽  
Ovarian Carcinoma ◽  
Phase I Trial ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma

2005 ◽  
Vol 55 (7) ◽  
pp. 761-774 ◽  
Author(s):  
Brian S. Choi ◽  
Paul M. Sondel ◽  
Jacquelyn A. Hank ◽  
Heidi Schalch ◽  
Jacek Gan ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Phase I ◽  
Phase I Trial ◽  
Combined Treatment ◽  
Interleukin 2

scholarly journals Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma

2006 ◽  
Vol 12 (15) ◽  
pp. 4619-4627 ◽  
Author(s):  
Jared A. Gollob ◽  
Catherine J. Sciambi ◽  
Bercedis L. Peterson ◽  
Tina Richmond ◽  
Monica Thoreson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Low Dose ◽  
Interleukin 2 ◽  
High Dose ◽  
Intravenous Bolus

scholarly journals Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3)

Blood ◽  
1988 ◽  
Vol 72 (5) ◽  
pp. 1826-1828
Author(s):  
S Shimizu ◽  
T Hirano ◽  
R Yoshioka ◽  
S Sugai ◽  
T Matsuda ◽  
...  
Keyword(s):  
Cell Line ◽  
Interleukin 2 ◽  
Recombinant Interferon ◽  
Plot Analysis ◽  
Recombinant Interleukin 2 ◽  
T Lymphoma ◽  
Dependent Growth ◽  
Stimulatory Factor ◽  
Recombinant Interferon Alpha ◽  
Necrosis Factor

A T lymphoma cell line (KT-3) established from a patient with Lennert's lymphoma showed macrophage-dependent growth. Macrophage-derived factors were able to replace the macrophage functions. Experiments using a variety of cytokines demonstrated that KT-3 proliferated in response to recombinant interleukin-2 (rIL-2), rIL-4, or rIL-6 but did not proliferate in response to rIL-1 alpha, rIL-1 beta, rIL-3, recombinant granulocyte colony-stimulating factor (rG-CSF), rGM-CSF, recombinant interferon-alpha (rIFN-alpha), rIFN-gamma, recombinant tumor necrosis factor (rTNF-alpha), or native IFN-beta. Polyclonal rabbit anti-IL-6 antibody almost completely neutralized the activities of macrophage- derived factors or IL-6 but not IL-2 or IL-4. Scatchard plot analysis demonstrated that KT-3 cells indeed express IL-6 receptors. The results indicate that the macrophage-derived factor that supports the growth of KT-3 is IL-6 and suggest that macrophage-derived IL-6 may play an important role in the histopathogenesis of Lennert's lymphoma.

Sign in / Sign up

Export Citation Format

Share Document